At Taj Pharma India Ltd., we position ourselves as a trusted pharmaceutical manufacturing, licensing, and development partner for regulated and semi-regulated markets worldwide. With a strong foundation in WHO-GMP compliant manufacturing, robust regulatory experience, and a diversified development pipeline, we actively engage in regional licensing, in-licensing, co-development, and commercialization partnerships across multiple therapeutic segments.
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Bilastine | BILATAJ | Anti-Allergic / Antihistamine | Tablet | 10 mg, 20 mg | II |
| Diclofenac Sodium + Paracetamol | DICLOTAJ-P | Analgesic / NSAID | Tablet | As per label | II |
| Esomeprazole | ESOTAJ | Anti-Ulcer / PPI | Tablet | 20 mg | II |
| Escitalopram | ESCITAJ | Antidepressant / SSRI | Tablet | 10 mg, 20 mg | I |
| Itopride Hydrochloride | ITOPRITAJ | Gastroprokinetic | Tablet | 50 mg | III |
| Micronized Purified Flavonoid Fraction (MPFF) | FLAVOTAJ | Vascular / Venotonic | Tablet | 500 mg | III |
| Moxonidine | MOXONITAJ | Antihypertensive | Tablet | 0.2 mg | I |
| Pancreatin | PANCRETAJ | Digestive Enzyme | Capsule / Tablet | 10,000 IU, 25,000 IU | III |
| Rosuvastatin | ROSUTAJ | Lipid-Lowering / Statin | Tablet | 10 mg | II |
| Tamsulosin | TAMTAJ | Urology / BPH | Capsule | 0.4 mg | II |
| Tretinoin | TRETOTAJ | Dermatology / Anti-Acne | Cream | 0.05% w/w | IV |
| Venlafaxine | VENLATAJ | Antidepressant / SNRI | Tablet | 37.5 mg, 75 mg, 150 mg | I |
| Febuxostat | FEBUTAJ | Anti-Gout | Tablet | 80 mg, 120 mg | II |
| Atomoxetine Hydrochloride | ATOMOXTAJ | ADHD / CNS | Capsule | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg | I |
Our Unit-1 Sarigam facility stands as a core pillar of our global partnership strategy, supported by an expanding Unit-2 product grid that is carefully aligned with evolving international market demand. Together, these units enable us to deliver ready-to-license dossiers, near-term submissions, and advanced development programs with speed, quality, and long-term scalability.
Unit-1 Sarigam: Licensing & Partnership Grid Overview
ANDA-Approved and Near-Term Submission Dossiers
Unit-1 Sarigam hosts a mature portfolio of ANDA-approved and submission-ready dossiers, developed to meet stringent international regulatory expectations. Several products have already been initiated at the plant level, ensuring rapid tech transfer, validation, and commercialization for partners.
Our Unit-1 grid is ideally suited for:
- Regional licensing and exclusive distribution
- Co-development and joint regulatory submissions
- Commercial manufacturing and long-term supply agreements
Each dossier is supported by robust CMC documentation, validated manufacturing processes, and scalable production capabilities, significantly reducing partner risk and time-to-market.
Strategic Expansion: Unit-2 Product Grid Development
Market-Driven Product Inclusion Model
In parallel with Unit-1 operations, we are actively evaluating additional product inclusions under Unit-2, guided by direct market interest, partner inquiries, and regional demand intelligence. This approach ensures that Unit-2 investments are commercially viable, demand-backed, and strategically aligned with partner growth plans.
We strongly encourage partners to share specific product interests, tender requirements, or pipeline gaps, enabling us to prioritize development that delivers mutual commercial advantage.
Priority Products Under Evaluation for Unit-2
We are currently inviting market interest and partnership discussions for the following priority molecules:
- Bumetanide Tablets
- Phenytoin Sodium Extended-Release Capsules
- Ursodeoxycholic Acid Capsules
- Valaciclovir Tablets
These products have been identified based on global prescribing relevance, lifecycle sustainability, and strong regulatory pathways, making them ideal candidates for mid- to long-term regional partnerships.
Unit-2 Product Grid Highlights
READY / ANDA-Approved Dossiers
Our Unit-2 grid already includes a robust basket of ANDA-approved and market-ready products, enabling immediate licensing and commercialization:
- Gabapentin Capsules
- Levetiracetam Tablets
- Colestipol Tablets
- Diclofenac Potassium Tablets
- Tizanidine Capsules
- Desipramine Tablets
- Isosorbide Mononitrate Extended-Release Tablets
- And multiple additional products across key therapy areas
These dossiers are backed by validated stability data, reproducible manufacturing processes, and scalable commercial batch capability, making them ideal for fast-track market entry.
Stability Charged – Dossiers Ready
Several high-value molecules have completed formulation development and stability charging, with dossiers ready for partner-driven submissions:
- Pimozide Tablets
- Avatrombopag Tablets
- Bismuth Subcitrate + Metronidazole + Tetracycline Capsules
- Oxaprozin Capsules
- Pyridostigmine Tablets
These products are particularly attractive for partners seeking pipeline depth with reduced development timelines.
Dossiers Planned by Q1–Q2 2026
Our forward-looking development roadmap includes strategic molecules scheduled for dossier finalization by Q1–Q2 2026, ensuring continuity and long-term portfolio strength:
- Brivaracetam Tablets
- Edoxaban Tablets
- Amlodipine + Atorvastatin Fixed-Dose Combinations
- Mesalamine Delayed-Release Tablets
This planned pipeline reflects our commitment to cardiovascular, CNS, and gastroenterology segments with sustained global demand.
Advanced Development / Prototype Completed
Taj Pharma’s R&D ecosystem supports advanced development and prototype-completed programs across complex and high-value therapeutic areas, including:
- Sacubitril + Valsartan
- Rivaroxaban
- Semaglutide (Oral)
- Bempedoic Acid
- Obeticholic Acid
These programs span CNS, cardiovascular, metabolic, gastrointestinal, renal, and rare disease segments, offering partners opportunities to enter premium and differentiated markets with strong lifecycle potential.
Literature-Stage and Early-Phase Pipeline
Our innovation-driven pipeline also includes literature-backed and early-phase molecules positioned for next-generation portfolio expansion:
- Resmetirom
- Cenobamate
- Finerenone
- Lumateperone
- And other emerging global therapies
These assets are ideal for co-development, risk-sharing, and future-focused partnerships.
Flexible Partnership Models Tailored to Your Market
We offer customizable collaboration structures designed to align with partner strategy, regulatory capability, and commercial objectives:
- Regional licensing and exclusive partnerships
- In-licensing and portfolio expansion
- CMO / CDMO manufacturing solutions
- Profit-sharing and royalty-based commercialization models
- Joint development and regulatory submission partnerships
Our approach is partner-centric, ensuring transparency, technical depth, and long-term value creation.
Why Partner with Taj Pharma India Ltd.
- WHO-GMP compliant manufacturing infrastructure
- Proven experience in regulated and emerging markets
- Strong CMC, formulation, and scale-up expertise
- Diverse therapy coverage with future-ready pipeline
- Agile decision-making and partner-aligned development
We combine scientific rigor with commercial pragmatism, enabling partners to achieve sustainable growth with reduced execution risk.
Connect With Us for Strategic Discussions
We welcome discussions on specific product interests, regional opportunities, and ongoing inquiries. Our technical and business development teams are prepared to engage in confidential, solution-driven conversations and align development priorities with your market needs.
TAJ PHARMA INDIA LTD.
Plot No. 1019, Vill. Sarigam, G.I.D.C.,
Road No. 10, Dist. Valsad,
Gujarat, India – 396155
Plant Location: https://g.co/kgs/WrD9gQQ
For Assistance, Contact:
+91 90995 11459 / +91 99040 00567






